Last update July 18, 2022

メロキシカム

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

It is a non-steroidal anti-inflammatory (NSAID), selective inhibitor of cyclooxygenase-2 (COX-2) that is used in the treatment of rheumatoid arthritis and other rheumatic diseases. Oral administration once daily.

At latest update, relevant information on excretion into breast milk was not found.

Due to a high serum-protein-binding capacity, excretion into breast milk seems to be unlikely.

Expert authors consider the use of meloxicam to be probably safe during breastfeeding (Briggs 2015). A similar agent, piroxicam, is classified as compatible with breastfeeding by the American Academy of Pediatrics

Until more information on this drug is available, another know therapeutic alternative should be preferred, especially in cases of breastfeeding an infant younger than one month or prematures.

Alternatives

  • Celecoxib (Safe product and/or breastfeeding is the best option.)
  • Ibuprofen (Safe product and/or breastfeeding is the best option.)
  • Paracetamol (Safe product and/or breastfeeding is the best option.)
  • Piroxicam (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

メロキシカム is Meloxicam in Japanese.

Is written in other languages:

Group

メロキシカム belongs to this group or family:

Tradenames

Main tradenames from several countries containing メロキシカム in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 89 %
Molecular weight 351 daltons
Protein Binding > 99.5 %
VD 0.14 - 0. 21 l/Kg
pKa 4.47 -
Tmax 2 - 6 hours
20 hours

References

  1. Boehringer. Meloxicam. Drug Summary. 2014 Full text (in our servers)
  2. AEMPS. Meloxicam. Ficha técnica. 2012 Full text (in our servers)
  3. Türck D, Roth W, Busch U. A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol. 1996 Abstract

Total visits

942

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM